What is EW stock price target for 2026?

WallStSmart's 12-month price target for Edwards Lifesciences Corp is $53.88, representing 33.7% downside from the current price of $81.22.

What is EW stock forecast?

Edwards Lifesciences Corp forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is EW undervalued based on price targets?

Our DCF intrinsic value for Edwards Lifesciences Corp is $264.83, against a current price of $81.22. The margin of safety is 70.04%.

Edwards Lifesciences Corp

NYSE: EW · HEALTHCARE · MEDICAL DEVICES

$81.22

-1.29% today

Updated 2026-04-29

Market cap

$46.83B

P/E ratio

43.90

P/S ratio

7.43x

EPS (TTM)

$1.85

Dividend yield

—

52W range

$72 – $88

Volume

5.0M

Market cap

$46.83B

P/E ratio

43.90

P/S ratio

7.43x

EPS (TTM)

$1.85

Dividend yield

—

52W range

$72 – $88

Volume

5.0M

Edwards Lifesciences Corp (EW) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$81.22

Consensus

$96.47

+18.78%

2030 Target

$202.63

+149.48%

DCF

$264.83

+70.04% MoS

Current price

$81.22

Analyst consensus

$96.47

+18.78%

2030 Target

$202.63

+149.48%

Intrinsic (DCF)

$264.83

+70.04% MoS

21 analysts:

14 Buy7 Hold0 Sell

Management guidance

Edwards Lifesciences guided to 2026 revenue of $6.88B (13.39% growth) and 2027 revenue of $7.55B (9.78% growth) based on structural heart device strength, TAVR market expansion, and new product launches including EVOQUE tricuspid valve system. Management emphasized continued momentum in their core structural heart franchise with sustained double-digit growth in TAVR procedures.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$332.30

$9.7B Rev × 20x P/S

Base case (2030)

$202.63

$9.7B Rev × 12x P/S

Bear case (2030)

$137.79

$9.7B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$6.0B	$5.4B	$6.1B	$6.9B	$7.5B	$8.2B	$9.0B	$9.7B
Revenue growth	—	-9.4%	11.5%	13.4%	9.8%	9.2%	8.7%	8.3%
EPS	$2.51	$2.62	$2.56	$3.01	$3.37	$3.75	$4.12	$4.51
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$145.89	$153.99	$170.21	$186.42	$202.63

Catalysts & risks

Growth catalysts

+ EVOQUE tricaspid valve system expansion (FDA approved US/EU, TRISCEND II 2-year data showing sustained benefits and lower mortality)

+ TAVR market share gains and procedure volume growth (structural heart is largest revenue segment)

+ Pascal Ace mitral valve device adoption and international expansion

+ Critical Care segment recovery and innovation pipeline execution

+ EchoNavigator AI-powered imaging system partnership with Philips (FDA cleared) improving procedure outcomes

Key risks

- TAVR market saturation in developed markets; procedural growth dependent on aging population expansion

- Competitive pressure from Boston Scientific, Abbott, and Medtronic in structural heart devices

- Regulatory delays or unfavorable outcomes in clinical trials for new indications

- Reimbursement rate pressures from CMS and international payers

- Heavy R&D spending ($1.06B annually) diluting near-term profitability despite revenue growth

Methodology

Edwards Lifesciences Corp's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 21 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.